中文 | English


赵振江简介


博士，男，华东理工大学药学院副教授，硕士研究生导师。

1986年河北师大化学系学士；1989年西北大学有机合成硕士；2004年华东理工大学应用化学博士。1990-2001年在中国乐凯胶片集团公司研究院工作；1999年在德国Merseburg技术大学做访问学者；2004-2010年在上海药企研发部工作；2005-2008年在上海交通大学和企业博士后工作站从事博士后研究；2010年至今在华东理工大学药学院李洪林教授课题组从事新药研发中的结构优化设计、药物合成和知识产权部分工作。

研究方向为新药研发工作中的药物化学、有机合成等。包括各种激酶抑制剂药物研发，主要包括抗肿瘤药物、代谢性疾病药物、免疫抑制剂和抗疟药物等新药研发。主持申请项目主要包括国家自然科学基金面上项目（2014），重大新药创制科技重大专项（2018）等，参与多项科技部、上海市科委项目研究。近年在国外期刊J. Med. Chem.、Scientific Reports、Eur. J. Med. Chem.、Med. Chem. Commun.等发表文章40余篇；作为主要发明人参与发明专利申请50余件，中国授权专利18件；参与完成PCT专利18件，其中8件正在进入国外30多个国家，已经获得国外授权专利4件；参与课题组完成多件专利许可或转让。作为通讯作者协助钱旭红院士完成专著撰写Chemical Biotechnology and Bioengineering（RSC Green Chemistry, Royal Society of Chemistry; ISBN 978-1-84973-801-1）。


地址：实验18楼1500；联系电话：64253962；邮箱：zhjzhao@ecust.edu.cn。


近期代表文章（通讯作者）：

  1. Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes; Shiliang Li, Chun Qin, Shichao Cui, Hongling Xu, Fangshu Wu, Jiawei Wang, Mingbo Su, Xiaoyu Fang, Dan Li, Qian Jiao, Ming Zhang, Chunmei Xia, Lili Zhu, Rui Wang, Jia Li, Hualiang Jiang, Zhenjiang Zhao*, Jingya Li*, and Honglin Li*; J. Med. Chem., 2019, 62 (5), pp 2348–2361.

  2. Xu, L.; Li, W.; Diao, Y.; Sun, H.; Li, H.; Zhu, L.; Zhou, H.; Zhao, Z.*, Synthesis, Design, and Structure(-)Activity Relationship of the Pyrimidone Derivatives as Novel Selective Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase. Molecules2018,23.

  3. Li, S.; Xu, H.; Cui, S.; Wu, F.; Zhang, Y.; Su, M.; Gong, Y.; Qiu, S.; Jiao, Q.; Qin, C.; Shan, J.; Zhang, M.; Wang, J.; Yin, Q.; Xu, M.; Liu, X.; Wang, R.; Zhu, L.; Li, J.; Xu, Y.; Jiang, H.; Zhao, Z.*; Li, J.; Li, H., Discovery and Rational Design of Natural-Product-Derived 2-Phenyl-3,4-dihydro-2H-benzo[f]chromen-3-amine Analogs as Novel and Potent Dipeptidyl Peptidase 4 (DPP-4) Inhibitors for the Treatment of Type 2 Diabetes. J Med Chem2016,59, 6772-90.

  4. Zhou, W.; Li, S.; Lu, W.; Yuan, J.; Xu, Y.; Li, H.; Huang, J.; Zhao, Z.*, Isoindole-1,3-dione derivatives as RSK2 inhibitors: synthesis, molecular docking simulation and SAR analysis. Med. Chem. Commun. 2016,7, 292-296.

  5. Li, S.; Luan, G.; Ren, X.; Song, W.; Xu, L.; Xu, M.; Zhu, J.; Dong, D.; Diao, Y.; Liu, X.; Zhu, L.; Wang, R.; Zhao, Z.*; Xu, Y.; Li, H., Rational Design of Benzylidenehydrazinyl-Substituted Thiazole Derivatives as Potent Inhibitors of Human Dihydroorotate Dehydrogenase with in Vivo Anti-arthritic Activity. Scientific reports2015,5, 14836.

  6. Yang, L.; Liu, W.; Mei, H.; Zhang, Y.; Yu, X.; Xu, Y.; Li, H.; Huang, J.; Zhao, Z.*, Synthesis and biological evaluation of pentanedioic acid derivatives as farnesyltransferase inhibitors. Med. Chem. Commun. 2015,6, 671-676.

  7. Yuan, J.; Zhao, Z.*; Zhu, W.; Li, H.; Qian, X.; Xu, Y., New strategy for the synthesis of 2-phenylbenzimidazole derivatives with sodium perborate (SPB) as oxidant. Tetrahedron2013,69, 7026-7030.

  8. Gao, R.; Liao, S.; Zhang, C.; Zhu, W.; Wang, L.; Huang, J.; Zhao, Z.*; Li, H.; Qian, X.; Xu, Y., Optimization of heterocyclic substituted benzenesulfonamides as novel carbonic anhydrase IX inhibitors and their structure activity relationship. European journal of medicinal chemistry2013,62, 597-604.

  9. Zhong, Y.; Xue, M.; Zhao, X.; Yuan, J.; Liu, X.; Huang, J.; Zhao, Z.*; Li, H.; Xu, Y., Substituted indolin-2-ones as p90 ribosomal S6 protein kinase 2 (RSK2) inhibitors: Molecular docking simulation and structure-activity relationship analysis. Bioorganic & medicinal chemistry2013,21, 1724-34.

  10. Xue, M.; Xu, M.; Lu, W.; Huang, J.; Li, H.; Xu, Y.; Liu, X.;Zhao, Z.*, Synthesis, activity evaluation, and docking analysis of barbituric acid aryl hydrazone derivatives as RSK2 inhibitors. J Enzyme Inhib Med Chem2013,28, 747-52.